Exaggerated response of arginine vasopressin-enhanced green fluorescent protein fusion gene to salt loading without disturbance of body fluid homeostasis in rats.
We examined the effects of chronic salt loading on the hypothalamic expressions of the enhanced green fluorescent protein (eGFP), arginine vasopressin (AVP) and oxytocin (OXT) genes in AVP-eGFP transgenic rats that expressed eGFP in the hypothalamic AVP-containing neurones. In these rats, salt loading for 5 days caused a marked increase of the eGFP fluorescence in the magnocellular divisions of the paraventricular nucleus (PVN), the supraoptic nucleus (SON) and the internal layer of the median eminence. Expression of the eGFP gene was increased seven- to eight-fold in the PVN and SON of salt-loaded rats in comparison with euhydrated rats. By contrast, none of these changes were observed in the suprachiasmatic nucleus. The expression of the AVP and OXT genes was increased 1.5- to two-fold in the PVN and SON of salt-loaded nontransgenic (control) and transgenic rats. There were no differences in the expression levels of the AVP and OXT genes in the PVN and SON between nontransgenic (control) and transgenic animals under normal conditions and after salt loading. In the posterior pituitary gland, the intensity of the eGFP fluorescence did not change after salt loading for 5 days, but increased after 10 days of salt loading. Upon salt loading, significant increases in the plasma AVP concentrations, plasma osmolality and plasma Na+ were observed. Furthermore, there were no significant differences in changes of water intake, food intake, urine volume, urine osmolality, urine Na+ concentrations, and the body weights in both models under normal or salt-loaded conditions. Our results show that the response of the AVP-eGFP fusion gene to chronic salt loading is exaggerated, and humoral responses such as AVP and OXT and the body fluid homeostasis are maintained in AVP-eGFP transgenic rats. The AVP-eGFP transgenic rat gives us a new opportunity to study the dynamics of the AVP system in vivo.
Fujio
T
T
Department of Occupational Health, Matsushita Science Center of Industrial Hygiene, Kadoma, Japan.
Fujihara
H
H
Shibata
M
M
Yamada
S
S
Onaka
T
T
Tanaka
K
K
Morita
H
H
Dayanithi
G
G
Kawata
M
M
Murphy
D
D
Ueta
Y
Y
D000818:Animals; D030801:Animals, Genetically Modified; D001127:Arginine Vasopressin / Q000096:biosynthesis* / Q000235:genetics* / Q000502:physiology; D044089:Galanin-Like Peptide / Q000378:metabolism; D049452:Green Fluorescent Proteins / Q000096:biosynthesis / Q000235:genetics; D006706:Homeostasis / Q000502:physiology*; D017403:In Situ Hybridization; D008297:Male; D008856:Microscopy, Fluorescence; D009994:Osmolar Concentration; D010121:Oxytocin / Q000096:biosynthesis / Q000097:blood / Q000502:physiology; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D011863:Radioimmunoassay; D051381:Rats; D017208:Rats, Wistar; D012965:Sodium Chloride / Q000494:pharmacology*; D013493:Suprachiasmatic Nucleus / Q000187:drug effects / Q000378:metabolism; D014882:Water-Electrolyte Balance / Q000187:drug effects / Q000502:physiology*
D044089:Galanin-Like Peptide; D012333:RNA, Messenger; D001127:Arginine Vasopressin; D049452:Green Fluorescent Proteins; D012965:Sodium Chloride; D010121:Oxytocin